Our mission is to provide innovative, blood-based diagnostics that change medical practice and improve the lives of patients with lung cancer.
We are a molecular diagnostics company at the forefront of innovation in oncology. We discover, develop and deliver blood-based diagnostics to answer unmet clinical questions across the continuum of lung cancer and improve the standard of care for patients.
We see both sides of lung cancer with our Biodesix Lung Reflex® testing strategy by integrating the GeneStrat® genomic test and the VeriStrat® proteomic test. Results within 72-hours can inform a comprehensive treatment strategy and expedite time to treatment. A fast result turnaround time can reduce a patient’s time from diagnosis to treatment start.
In addition to our on-market products, we collaborate with biopharma to help optimize their clinical development programs with blood-based diagnostics. By using cutting edge techniques in machine learning alongside our comprehensive multi-omic approach, looking at biomarkers in both the tumor and host, our service offering helps partners develop, commercialize and find optimal combinations of novel therapeutics. Our established product development process and quality systems support diagnostic development up to and including companion diagnostic commercialization.
All clinical and biopharma service testing is performed in our best-in-class diagnostic laboratory, certified by CAP, CLIA, NYS CLEP and ISO 13485.